Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Platinum-sensitive Relapsed Epithelial Ovarian Cancer Clear all

Conditions: Ovarian Cancer, Ovarian Cancer Recurrent
Interventions: COM701, Normal Saline; Drug
Lead sponsor: Compugen Ltd; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Augusta, Georgia • Chicago, Illinois • Warrenville, Illinois + 10 more

Conditions: Platinum-Sensitive Ovarian Cancer in First Relapse
Interventions: Farletuzumab, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 35
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 32 more

Conditions: Ovarian Cancer
Interventions: Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 110
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more

Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: pegfilgrastim, carboplatin, docetaxel; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 3
States / cities: Seattle, Washington

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Advanced Solid Tumor With Evidence of Germline or Somatic BRCA
Interventions: Rucaparib; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 6
States / cities: San Francisco, California • Sarasota, Florida • Boston, Massachusetts + 3 more

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Oral rucaparib; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 36
States / cities: Anchorage, Alaska • Tucson, Arizona • Fullerton, California + 28 more

Conditions: Ovarian Cancer
Interventions: AZD2281, matching placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2023
U.S. locations: 11
States / cities: Berkeley, California • San Francisco, California • West Hollywood, California + 6 more

Conditions: Ovarian Cancer
Interventions: Carboplatin, Gemcitabine, BNC105P; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Chicago, Illinois • Indianapolis, Indiana

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions: Farletuzumab, Chemo Plus Far; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 18
States / cities: San Diego, California • Indianapolis, Indiana • Covington, Louisiana + 15 more

Conditions: Ovarian Cancer
Interventions: Olaparib tablets; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Duarte, California • Newport Beach, California • Roseville, California + 10 more

Conditions: Fallopian Tube Cancer, Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions: everolimus, carboplatin, pegylated liposomal doxorubicin hydrochloride, laboratory biomarker analysis; Drug · Other
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions: OLAPARIB; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 35
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 29 more

Conditions: Ovarian Cancer
Interventions: Olaparib, Ceralasertib, Placebo to match olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 22
States / cities: Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more

Conditions: Platinum Sensitive Relapsed Ovarian Cancer
Interventions: OLAPARIB, PLACEBO; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 96 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 15
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Chemotherapy, Rucaparib; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 349 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Denver, Colorado • Augusta, Georgia

Conditions: Ovarian Cancer, Neoplasms, Ovarian
Interventions: topotecan, CARBOPLATIN; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 18
States / cities: Los Angeles, California • Orange, California • Poway, California + 15 more

Conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions: Trabectedin, DOXIL, Dexamethasone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 75
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more

Conditions: Ovarian Cancer
Interventions: Docetaxel, Carboplatin; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 19
States / cities: Fort Myers, Florida • Jupiter, Florida • Orlando, Florida + 16 more

Conditions: Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
Interventions: Olaparib 300mg tablets, Placebo to match olaparib 300mg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 16
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 11 more

Conditions: Epithelial Ovarian Cancer
Interventions: MORAb-003; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Chula Vista, California • San Antonio, Texas

Conditions: Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions: OLAPARIB, Single agent chemotherapy; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 22
States / cities: Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 19 more

Conditions: Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
Interventions: Torvutatug samrotecan, Bevacizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 26
States / cities: Anchorage, Alaska • Miami, Florida • Indianapolis, Indiana + 21 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions: Pazopanib, Doxil; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 4
States / cities: Fort Myers, Florida • Orlando, Florida • Cincinnati, Ohio + 1 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: Rucaparib, Placebo; Drug
Lead sponsor: pharmaand GmbH; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 22
States / cities: Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more

Search by objective public record fields.

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

An Open Label Extension Study of the Efficacy of MORAb-003

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)